Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial

Table 2 Summary of co-primary and key secondary endpoints^a

Endpoint	Rimegepant 75 mg n = 537	Placebo n = 537	Risk Difference^b (95% CI)	p value^c
Co-Primary
Pain freedom at 2 h post-dose	98 (18.2%)	57 (10.6%)	7.6 (3.5, 11.8)	0.0004
MBS freedom at 2 h post-dose	258 (48.0%)	171 (31.8%)	16.2 (10.4, 22.0)	< 0.0001
Key Secondary
Pain relief at 2 h post-dose	351 (65.4%)	256 (47.7%)	17.8 (12.0, 23.7)	< 0.0001
Normal function at 2 h post-dose ^d	176 (38.5%)	110 (23.8%)	14.7 (8.8, 20.6)	< 0.0001
Rescue Medication use within 24 h post-dose	28 (5.2%)	75 (14.0%)	−8.9 (−12.4, −5.4)	< 0.0001
Sustained pain freedom from 2 to 24 h post-dose	82 (15.3%)	43 (8.0%)	7.2 (3.4, 11.1)	0.0002
Sustained pain freedom from 2 to 48 h post-dose	78 (14.5%)	39 (7.3%)	7.2 (3.5, 10.9)	0.0001

MBS Most bothersome symptom
^aIncludes all randomized Chinese participants who took study treatment, had a migraine of moderate or severe intensity at the time of treatment, and provided at least one post-treatment efficacy data point. See methods section for details on handling of missing data and definition of failures
^bRimegepant vs. placebo, calculated from Mantel–Haenszel test stratified by preventive migraine medication use
^cRimegepant vs. placebo, calculated from Cochran-Mantel-Haenszel test stratified by preventive migraine medication use. All p values are nominal
^dAmong participants with functional disability at time of dosing (rimegepant, n = 457, placebo, n = 462)

ISSN: 1129-2377